DTM SCS endurance therapy is a modified and lower-energy variation of Medtronic’s Differential Target Multiplexed (DTM) SCS therapy for chronic overall, back or leg pain
Medtronic operational headquarters in Fridley, Minnesota, US. (Credit: Group29 at English Wikipedia)
Medtronic announced that its DTM spinal cord stimulation (SCS) endurance therapy has demonstrated a meaningful pain relief in an on-label, prospective and multi-centre study.
At three months, patients treated with DTM SCS endurance therapy shown meaningful pain relief as measured by a 3.9cm reduction in overall pain on the 10cm Visual Analog Scale (VAS), said the company.
The VAS is a mostly used and accepted measure for pain intensity, which captures patient-reported pain levels on a scale of 0-10.
DTM SCS endurance therapy is a modified and lower-energy variation of Medtronic’s Differential Target Multiplexed (DTM) SCS therapy for chronic overall, back or leg pain.
Medtronic also stated that patients reported an average 4.3cm decrease in back pain, and an average 5.3cm decrease in leg pain.
According to the company, the three-month results are in line with an earlier feasibility study and add to the body of DTM SCS evidence showing that DTM SCS endurance therapy can offer effective pain relief along with additional quality of life and functional benefits for patients
The three-month data has also demonstrated that 69% of patients improved to a less disabled category as measured by the Oswestry Disability Index.
Medtronic neuroscience portfolio’s neuromodulation business pain therapies general manager and vice president Charlie Covert said: “Every patient with chronic pain has their own unique needs, and Medtronic is committed to offering solutions that personalize care for our patients.
“For many, especially those who need or prefer a recharge-free SCS solution, our new DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life, and offering meaningful device longevity.”
The company will conduct additional follow-up assessments at six and 12 months on enrolled patients in the study.
In November last year, Medtronic unveiled positive five-year clinical data for its CoreValve and Evolut transcatheter aortic valve implantation (TAVI) platforms from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial.